Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMUX
SellHot AirImmunic, Inc. · Healthcare · United States · $210M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Immunic, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel oral small molecule therapies for chronic inflammatory and autoimmune diseases. The company's pipeline includes drug candidates targeting pathways involved in conditions such as multiple sclerosis, psoriasis, and inflammatory bowel disease. Its competitive strategy centers on identifying and advancing innovative compounds with the potential to address significant unmet medical needs in immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 10.0M | — |
| EPS | -10.91 | -7.00 | -10.00 | -6.20 | — | -3.55 | -3.57 | -2.43 | — |
| Shares | 13.6M | 13.6M | 9.0M | 12.0M | -11.6% | 13.6M | — | — | — |
| Debt | 1.6M | 1.3M | 1.0M | 0.6M | -28.3% | 0.6M | — | — | — |
| Equity | 113.7M | 28.9M | 18.4M | -6.7M | -59.7% | — | — | — | — |
| Op CF | -65.1M | -70.8M | -84.8M | -85.8M | — | -87.7M | — | — | — |
| Inv CF | -9.7M | 9.5M | -0.3M | -0.2M | — | — | — | — | — |
| Fin CF | 95.8M | 1.0M | 74.5M | 65.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMUX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMUX | Immunic, Inc.(you) | $210M | 28 | Sell |
| DTIL | Precision BioSciences, Inc. | $215M | 27 | Sell |
| NKTX | Nkarta, Inc. | $198M | 25 | Sell |
| ANTX | AN2 Therapeutics, Inc. | $211M | 33 | Sell |
| EQ | Equillium, Inc. | $152M | 29 | Sell |
| OKUR | OnKure Therapeutics, Inc. | $153M | 27 | Sell |
| ACOG | Alpha Cognition Inc. Common Stock | $199M | 35 | Sell |
| NRXP | NRx Pharmaceuticals, Inc. | $154M | 24 | Sell |
| CDXS | Codexis, Inc. | $174M | 21 | Sell |
| WHWK | Whitehawk Therapeutics, Inc. | $263M | 35 | Hold |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%